28.32
0.33%
-0.095
Immunocore Holdings Plc Adr stock is traded at $28.32, with a volume of 279.02K.
It is down -0.33% in the last 24 hours and down -12.63% over the past month.
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
See More
Previous Close:
$28.42
Open:
$28.7
24h Volume:
279.02K
Relative Volume:
1.04
Market Cap:
$1.42B
Revenue:
$345.60M
Net Income/Loss:
$-79.01M
P/E Ratio:
-22.09
EPS:
-1.2822
Net Cash Flow:
$-18.62M
1W Performance:
-2.02%
1M Performance:
-12.63%
6M Performance:
-19.35%
1Y Performance:
-51.41%
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Name
Immunocore Holdings Plc Adr
Sector
Industry
Phone
01235 5430281
Address
90 PARK DRIVE, OXFORDSHIRE
Compare IMCR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
28.32 | 1.42B | 345.60M | -79.01M | -18.62M | -1.6045 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Nov-11-24 | Downgrade | Mizuho | Outperform → Neutral |
Oct-24-24 | Initiated | UBS | Sell |
Oct-07-24 | Downgrade | Guggenheim | Buy → Neutral |
Apr-29-24 | Initiated | Leerink Partners | Outperform |
Nov-20-23 | Resumed | JP Morgan | Overweight |
Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
Oct-31-23 | Initiated | Robert W. Baird | Outperform |
Sep-13-23 | Upgrade | JP Morgan | Neutral → Overweight |
Sep-13-23 | Initiated | Needham | Buy |
Aug-16-23 | Initiated | CapitalOne | Overweight |
Jul-17-23 | Initiated | Canaccord Genuity | Hold |
Mar-31-23 | Initiated | Mizuho | Buy |
Mar-30-23 | Initiated | Guggenheim | Buy |
Mar-24-23 | Initiated | Bryan Garnier | Buy |
Dec-16-22 | Upgrade | Goldman | Neutral → Buy |
Nov-30-22 | Initiated | Barclays | Overweight |
Sep-09-22 | Initiated | Morgan Stanley | Overweight |
Sep-08-22 | Initiated | Ladenburg Thalmann | Buy |
Aug-08-22 | Initiated | Cowen | Outperform |
Aug-02-22 | Initiated | BTIG Research | Buy |
Feb-08-22 | Initiated | H.C. Wainwright | Buy |
Oct-20-21 | Initiated | Oppenheimer | Outperform |
Mar-02-21 | Initiated | Goldman | Neutral |
Mar-02-21 | Initiated | JP Morgan | Overweight |
Mar-02-21 | Initiated | Jefferies | Buy |
View All
Immunocore Holdings Plc Adr Stock (IMCR) Latest News
Disappointing data leads to Immunocore stock downgrade by Morgan Stanley - Investing.com South Africa
Immunocore stock hits 52-week low at $29.23 amid market challenges - Investing.com
Immunocore's SWOT analysis: TCR pioneer's stock faces pivotal year - Investing.com
All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy - Yahoo Finance
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study - Yahoo Finance
New Strong Buy Stocks for December 12th - Yahoo Finance
RZLT Stock Rises On FDA's Orphan Designation For Rare Disease Drug - Barchart
Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect? - MSN
Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know - MSN
New Strong Buy Stocks for November 26th - Yahoo Finance
Stack Capital Group announces normal course issuer bid - MSN
FATE Presents Encourgaing Data From Lupus Study, Stock Gains - Barchart
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study - Nasdaq
What will it take for small caps to finally outperform large caps on earnings, performance? - MSN
Immunocore (IMCR) Upgraded to Buy: Here's Why - MSN
Immunocore's SWOT analysis: biotech stock faces pivotal moment amid PRAME data - Investing.com India
FATE Q3 Earnings Beat On Higher Revenues, Pipeline In Focus - Barchart
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark - Barchart
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised - Barchart
Mizuho downgrades Immunocore stock to Neutral, slashes PT to $38 from $72 - Investing.com
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline In Focus - Barchart
Immunocore repays Pharmakon loan, ends agreement - Investing.com India
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up - Barchart
Immunocore Holdings earnings beat by $0.50, revenue topped estimates - Investing.com India
Immunocore shares maintain buy rating on HIV treatment potential - Investing.com
Immunocore Holdings PLC (IMCR) Q2 2024 Earnings Call Highlights: Strong US Growth and Strategic ... - Yahoo Finance
Immunocore stock hits 52-week low at $29.72 amid market challenges - Investing.com
Immunocore's SWOT analysis: biotech stock poised for growth amid clinical trials - Investing.com UK
Financial Fitness Check: Examining Immunocore Holdings plc ADR (IMCR)’s Key Ratios - The Dwinnex
Immunocore stock hits 52-week low at $32.07 amid market challenges - Investing.com
TD Cowen maintains Buy rating on Immunocore shares on ovarian cancer drug data - Investing.com India
Quarterly Metrics: Quick and Current Ratios for Immunocore Holdings plc ADR (IMCR) - The Dwinnex
Immunocore Holdings plc ADR (IMCR) is looking forward to a strong quarter - SETE News
Immunocore stock hits 52-week low at $32.84 amid market challenges - Investing.com
Ratios Revealed: Decoding Immunocore Holdings plc ADR (IMCR)’s Financial Health - The Dwinnex
Have you been able to find a good deal on Immunocore Holdings plc ADR’s shares? - US Post News
Immunocore Holdings plc (IMCR): Top ADR Stock According to Hedge Funds - Yahoo Finance UK
The growth track for Immunocore Holdings plc ADR (IMCR) has changed recently - SETE News
The Potential Rise in the Price of Sun Communities, Inc. (SUI) following insiders activity - Knox Daily
Insider Sale Alert: Terns Pharmaceuticals Inc [TERN] – Is it Time to sell? - Knox Daily
Immunocore Holdings plc ADR (IMCR) may enjoy gains as insiders got busy in the recent days - Knox Daily
Monitoring Brookline Bancorp, Inc. (BRKL) after recent insider movements - Knox Daily
Immunocore Holdings plc ADR [IMCR] Shares Fall -4.18% on Thursday - Knox Daily
Financial Health Report: Immunocore Holdings plc ADR (IMCR)’s Ratios Tell a Tale - The Dwinnex
Insider Sale: President Brian Hole Sells Shares of Willis Lease Finance Corp (WLFC) - Yahoo Finance UK
Immunocore Holdings Plc Adr Stock (IMCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunocore Holdings Plc Adr Stock (IMCR) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
St Leger Tina Amber | CHIEF HR OFFICER |
Apr 01 '24 |
Sale |
64.06 |
4,375 |
280,262 |
0 |
Berman David M | HEAD OF R&D |
Feb 28 '24 |
Option Exercise |
17.46 |
36,509 |
637,447 |
36,509 |
Berman David M | HEAD OF R&D |
Feb 28 '24 |
Sale |
68.59 |
36,509 |
2,504,158 |
0 |
Berman David M | HEAD OF R&D |
Feb 27 '24 |
Option Exercise |
17.46 |
54,938 |
959,217 |
54,938 |
Berman David M | HEAD OF R&D |
Feb 26 '24 |
Option Exercise |
17.46 |
28,553 |
498,535 |
28,553 |
Berman David M | HEAD OF R&D |
Feb 27 '24 |
Sale |
70.86 |
54,938 |
3,893,030 |
0 |
Berman David M | HEAD OF R&D |
Feb 26 '24 |
Sale |
70.65 |
28,553 |
2,017,288 |
0 |
St Leger Tina Amber | Chief HR Officer |
Jan 03 '24 |
Option Exercise |
29.87 |
4,375 |
130,681 |
4,375 |
St Leger Tina Amber | Chief HR Officer |
Jan 03 '24 |
Sale |
69.89 |
4,375 |
305,781 |
0 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):